Bristol-Myers Squibb Company
FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND PCSK9
Last updated:
Abstract:
The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
Status:
Application
Type:
Utility
Filling date:
16 Feb 2021
Issue date:
9 Sep 2021